Related Experiment Video
Updated: Sep 10, 2025
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance
Yutao Wang1, Fan Wang2, Qi Pan3
1Department of Urology, The First Hospital of China Medical University, Shenyang 110001, China; Department of Urology, Chinese Academy of Medical Sciences, Peking Union Medical College, Peking Union Medical College Hospital, Beijing 100005, China.
Abstract:
Prostate cancer (PCa) is one of the main causes of cancer-related mortality. The tumor microenvironment (TME) and the development of drug resistance pose significant challenges to effective cancer therapy. This review explores the integration of multi-omics proteomic approaches to decipher the complex interactions within the TME and the mechanisms driving resistance in PCa. We discuss how proteomics and genomics, transcriptomics, and metabolomics enhance our understanding of the molecular drivers of cancer progression, immune evasion, and treatment failure. Emphasis is placed on recent advances in proteomic profiling of the TME, including extracellular matrix components and immune regulators, and how single-cell proteomics provides insights into tumor heterogeneity. We also highlight the multi-omics role in identifying post-translational modifications and kinase pathways contributing to therapeutic resistance, and its implications for biomarker discovery and personalized medicine. The review concludes by addressing the clinical potential of multi-omics approaches and their future role in improving outcomes for prostate cancer patients.
Insights
This review highlights how multi-omics proteomic approaches can unravel the complexities of the prostate cancer tumor microenvironment and drug resistance. Understanding these interactions is key to developing new therapies and improving patient outcomes.
Area of Science:
- Oncology
- Proteomics
- Genomics
Background:
- Prostate cancer (PCa) remains a leading cause of cancer mortality, with the tumor microenvironment (TME) and drug resistance presenting major therapeutic hurdles.
- Effective PCa treatment is challenged by the intricate TME and the development of resistance mechanisms.
Purpose of the Study:
- To review the integration of multi-omics proteomic approaches for understanding PCa TME and drug resistance.
- To explore how combining proteomics with genomics, transcriptomics, and metabolomics can elucidate cancer progression and treatment failure.
Main Methods:
- Review of multi-omics studies integrating proteomics, genomics, transcriptomics, and metabolomics in prostate cancer.
- Analysis of proteomic profiling techniques for TME characterization, including extracellular matrix and immune components.
- Examination of single-cell proteomics for tumor heterogeneity insights.
Main Results:
- Multi-omics approaches enhance understanding of molecular drivers in PCa progression, immune evasion, and treatment failure.
- Proteomic profiling of the TME reveals key components like extracellular matrix and immune regulators.
- Single-cell proteomics offers insights into tumor heterogeneity and resistance mechanisms.
- Multi-omics identifies post-translational modifications and kinase pathways driving therapeutic resistance.
Conclusions:
- Multi-omics proteomic strategies are crucial for deciphering PCa TME complexity and resistance mechanisms.
- These approaches hold significant potential for biomarker discovery and advancing personalized medicine in PCa.
- The integration of multi-omics is vital for improving clinical outcomes for prostate cancer patients.
